Richard G. Stock, MD
Radium-223 (Xofigo) has efficacy in treating patients with prostate cancer and bone metastases, but is usually introduced into the patient's traetment plan after they have symptomatic disease. These symptoms are often painful, and the metastases can be difficult to treat at this stage. Moving radium-223 up in the treatment paradigm for these patients could provide better outcomes and longer survival, according to Richard G. Stock, MD, professor and director of genitourinary oncology at the Icahn School of Medicine at Mount Sinai in New York.
... to read the full story